secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2026-05-11T20:07:49+00:00
Accession:  0001815776-26-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M
---------------------------------------------------------------------------

- Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.
- Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.
- Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.
- Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.
- Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/0001815776-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/lenz-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001815776-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer